Kenvue

Kenvue Inc. emerged as an independent public company on May 4, 2023, following its separation from Johnson & Johnson's consumer health division through the largest U.S. IPO since 2021, raising $3.8 billion at a $41 billion valuation. The company represents the culmination of over 135 years of consumer healthcare heritage, inheriting iconic brands that have been household names for generations. Headquartered in Summit, New Jersey, Kenvue's mission centers on 'realizing the extraordinary power of everyday care,' transforming routine health and wellness moments into opportunities for consumers to take control of their wellbeing.

Kenvue's portfolio encompasses some of the most trusted and recognizable consumer health brands globally. The company operates through three strategic business segments: Self Care (including Tylenol, Benadryl, and Zyrtec for pain relief, allergy, and cold management), Skin Health and Beauty (featuring Neutrogena and Aveeno dermatologist-recommended skincare), and Essential Health (including Listerine oral care, Johnson's Baby products, and Band-Aid wound care). This diversified portfolio serves billions of consumers worldwide, with products distributed across retail, pharmacy, e-commerce, and healthcare professional channels in over 100 countries.

The company's independence from Johnson & Johnson positions it to focus exclusively on consumer health innovation while maintaining operational excellence. With approximately 22,000 employees globally distributed across North America (25%), EMEA (28%), APAC (28%), and LATAM (19%), Kenvue combines global scale with local market expertise. The company invests heavily in research and development, allocating $250 million toward R&D initiatives and maintaining strong relationships with dermatologists, pediatricians, and other healthcare professionals who recommend its products to patients.

In November 2025, Kimberly-Clark Corporation announced a definitive agreement to acquire Kenvue for a total enterprise value of $48.7 billion, expected to close in the second half of 2026. This transformative transaction will unite two iconic American consumer goods companies, creating a $32 billion global health and wellness leader with 10 billion-dollar brands. The combined entity will leverage complementary product portfolios, with Kimberly-Clark's expertise in personal care (Huggies, Kleenex, Cottonelle) merging with Kenvue's consumer health leadership.

For fiscal year 2024, Kenvue reported revenues of $15.5 billion with modest organic sales growth of 1.5%, reflecting challenges in a transitional period marked by leadership changes and strategic reviews. The company maintained a market capitalization of approximately $31 billion and demonstrated resilience through Q4 2024 with 1.7% organic sales growth. Under new leadership from CEO Kirk Perry, who assumed the role in November 2025, and CFO Amit Banati who joined from Kellanova in May 2025, Kenvue is pursuing a comprehensive strategic review to unlock shareholder value and position the company for accelerated growth as it prepares for its integration with Kimberly-Clark.